A Splice Variant of the ITF-2 Transcript Encodes a Transcription Factor That Inhibits MyoD Activity*

(Received for publication, November 15, 1995)

Ilona S. Skerjanc‡§, James Truong¶, Pascale Filion¶, and Michael W. McBurney¶¶

From the ‡Department of Biochemistry, Health Sciences Building, University of Western Ontario, London, Ontario N6A 5C1, Canada and the ¶Department of Medicine, University of Ottawa, and Ottawa Regional Cancer Centre, 501 Smyth Road, Ottawa, Ontario K1H 8L6, Canada

Proteins of the basic helix-loop-helix (bHLH) family are transcription factors that bind DNA containing the E box motif (CANNTG) found in the promoters of many muscle-specific genes. ITF-2 is a bHLH protein with widespread expression that is thought to form active heterodimers with MyoD, a muscle-specific bHLH transcription factor. We have isolated cDNAs derived from two alternatively spliced forms of mouse ITF-2, termed MITF-2A and -2B. These proteins differ in their N termini. Neither MITF-2A nor -2B transactivated the cardiac α-actin promoter, which contains an E box, when transfected into nonmuscle cells. In fact, MITF-2B inhibited MyoD activation of the cardiac α-actin promoter. This inhibitory activity required the N-terminal 83 amino acids since MITF-2A showed no inhibitory activity. In contrast, a mutant MITF-2B with deletion of the N-terminal 83 amino acids failed to inhibit MyoD-mediated transcriptional activation. MyoD activity was also inhibited by Id, a HLH protein, and this inhibition was reversed by the addition of excess E12 or MITF-2A. However, the inhibition of MyoD activity by MITF-2B was not reversed with E12 or MITF-2A. While Id is thought to inhibit MyoD by binding and sequestering potential dimerization partners, MITF-2B appears to inhibit MyoD activity by forming an inactive heterodimer with MyoD. Thus, differentially spliced transcripts of mouse ITF-2 encode different proteins that appear to dimerize with MyoD and activate or repress transcription.

During skeletal muscle development, a family of transcription factors of the bHLH1 class plays a pivotal role in inducing and maintaining the differentiated character of skeletal muscle (Olson, 1989; Weintraub et al., 1991; Sassoon, 1993). These transcription factors, MyoD, myf-5, myogenin, myf-6/MRF-4/ herculin (Davis et al., 1987; Braun et al., 1989; Edmondson and Olson, 1989; Olson, 1990; Rhodes and Konieczny, 1989; Wright et al., 1989; Brown et al., 1990; Miner and Wold, 1990) activate the transcription of many muscle-specific genes by binding to DNA at E box sites (CANNTG) within their promoters (Lassar et al., 1989).

The active forms of these transcription factors are thought to be heterodimers comprised of a myogenic bHLH protein and a ubiquitous E type bHLH protein (Lassar et al., 1991). The latter proteins are derived from alternatively spliced transcripts from two genes, one called E12 (also called E2A, E2-5, or ITF 1) (Murre et al., 1989a; Henthorn et al., 1990b; Nourse et al., 1990) and the other called ITF-2 (also called E2-2, SEF2, or TFE) (Henthorn et al., 1990a; Cornelissen et al., 1991; Javahery et al., 1991). The basic region of these transcription factors is responsible for binding to the E box sequence in DNA, while the HLH domain mediates dimerization. Homodimers of E12 are able to transactivate some E box-containing promoters, while homodimers of ITF-2 cannot (Henthorn et al., 1990a). Although homodimers of MyoD are inactive, heterodimers of MyoD and E12 or MyoD and ITF-2 can activate promoters containing E box sequences (Lassar et al., 1991). Thus, MyoD requires heterodimerization with ubiquitous E type proteins for activity. All of the E type bHLH proteins contain a conserved motif, designated the loop-helix (LH) motif, which is responsible for most of the transcriptional activation activity of these proteins (Quong et al., 1993).

Lineage-specific bHLH proteins exist in tissues other than muscle. MASH1 and MASH2 are bHLH proteins that are restricted to neuronal lineages (Johnson et al., 1990). They are mammalian homologues of the Drosophila achaete-scute genes. Tel-1, tal-2, and lyl-1 are bHLH proteins that are restricted to hematopoietic tissues (Chen et al., 1990; Xia et al., 1991; Melletin et al., 1989). These three proteins have been implicated in the development of human lymphoid malignancies. The neurogenic and the hematopoietic bHLH proteins heterodimerize with E12 protein (Murre et al., 1989b; Hsu et al., 1991; Voronova and Lee, 1994).

The protein Id has an HLH motif, but it lacks the basic domain. Id is believed to act as a negative regulator of other bHLH proteins through the formation of heterodimeric complexes that fail to bind DNA (Benezra et al., 1990). Id mRNA levels decrease upon terminal differentiation of several cell lines, including myoblasts, consistent with the idea that transcription from E box containing promoters is regulated by both activating and inhibitory transcription factors. Because no correlation is evident between the order of expression of the myogenic bHLH proteins and the appearance of specific contractile proteins (Ontell et al., 1993), it is possible that the presence of E type bHLH and inhibitory HLH proteins may participate in regulating myogenesis.

We have examined the effects of bHLH proteins on the activity of the muscle-specific cardiac α-actin promoter. The first...
440 bp of the human cardiac α-actin promoter contains one E box, which is essential for cardiac α-actin expression in skeletal muscle (Skerjanc and McBurney, 1994). We cloned cDNAs derived from mRNAs of cardiac α-actin promoter in transient transfection experiments (Pari et al., 1991; Sartorelli et al., 1990; Skerjanc and McBurney, 1994). We doned cDNAs derived from mRNAs of two alternatively spliced forms of mouse ITF-2, termed MITF-2A and -2B. Neither MITF-2A nor -2B transactivated the cardiac α-actin promoter. However, MITF-2B inhibited the transactivation of the cardiac α-actin promoter by MyoD while MITF-2A did not.

**Materials and Methods**

Polymerase Chain Reaction Amplification of ITF-2—The mouse ITF-2 probe used to screen the library was prepared as described previously (Skerjanc and McBurney, 1994). Briefly, PCR was performed with the following degenerate oligonucleotides: 1) AAAAAAGTTCA(A/C/T)(A/G)GGC(C/G)TGC(C/G)AGGGT; 2) AAAAAAGTTCA(A/C/T)(A/G)GGC(C/G)TGC(C/G)AGGGT. Oligonucleotide 1 represents a consensus for the basic domain of E12 (Murre et al., 1989a), HEB (Hu et al., 1992), ITF-2 (Henthorn et al., 1990a), and MyoD (Davis et al., 1987), and the boldface sequence is an ECoRI site. Oligonucleotide 2 represents a consensus for helix 2, and the boldface sequence is an EcoRI site. PCR was performed with 30 ng of cDNA, prepared as described below and 2 µg of each oligonucleotide in 100 µl with Taq polymerase (Life Technologies, Inc., BRL, Burlington, Canada) under standard conditions with annealing at 55 °C.

Fragments of several BHLH cDNAs were amplified, subcloned, and sequenced, as described previously (Skerjanc and McBurney, 1994). The amplified cDNA fragment encoding ITF-2 encompasses the conserved bHLH domain and has the following sequence: AACACCGCTGGCCGTATGGTCAGCTCCACCTGAAGAGCGACAAGCCC-AGCTTGGCCGTATGGTGCAGCTCCACCTGAAGAGCGACAAGGCGCAGAAGAGCTTCCTGCCCAACAAAGCGCCGT. The MITF-2 probes were prepared by replacing cold dCTP with 50 µCi [α-32P]dCTP during a PCR amplification with 10 ng of the amplified MITF-2 cDNA fragment.

cDNA Library Construction and Screening—Total RNA was isolated (Auffray and Rougeon, 1980) from day 6 Me2SO-treated P19 cells, which contained abundant cardiac muscle. Poly(A)+ RNA was selected by standard protocols (Sambrook et al., 1989). cDNA was primed with an oligo(dT) NotI primer-adapter and was synthesized with the superscript λ system for cDNA synthesis and cloning (Life Technologies, Inc.). SalI adapters were ligated to the ends. The cDNA was subsequently digested with NotI and size-fractionated by column chromatography, yielding 300 ng of size-selected cDNA. Some of this cDNA (30 ng) was used in a PCR reaction with the degenerate oligonucleotides to generate the ITF-2 probe, as described above. Part of this cDNA (20 ng) was used for a phage library that was digested with NotI and SalI and packaged using the BRL λ packaging system (Life Technologies, Inc., BRL, Burlington, Canada). A total of 2 × 108 plaques were obtained.

Standard procedures (Sambrook et al., 1989) were used to plate 500,000 plaques onto 10 × 150-mm plates. Plaques were transferred to Hybond-N and denatured by autodigestion for 2 min at 100 °C. DNA was cross-linked by UV irradiation, and the filters were hybridized for 16 h at 42 °C with the radiolabeled ITF-2 PCR product. Washing was performed for 30 min at room temperature in 2 × SSC, 0.2% SDS and for 15 min at 65 °C in 0.2 × SSC, 0.2% SDS. Hybridization was visualized by autoradiography. Ten positive plaques were identified from the 500,000-phage library, and six were isolated after three rounds of plaque purification.

ITF-2 Sequencing Analysis—Standard procedures (Sambrook et al., 1989) were used to purify the phage DNA and ligate the cDNA inserts into the NotI/SalI sites of pBluescript (KS orientation, Stratagene Cloning Systems, La Jolla, CA). The ends of all clones were sequenced with the dideoxy method (Sanger et al., 1980). The partial E12 cDNA was cloned into pBluescript and sequenced, as described previously (Skerjanc et al., 1994). The partial E12 cDNA was cloned into pBluescript and sequenced, as described previously (Skerjanc et al., 1994).

**Plasmid Constructs**—All of the eukaryotic expression constructs contained the mouse pgk-1 promoter (Adra et al., 1987) driving the specified cDNA. PGK-MITF-2B contains a 3.2-kb SspI/NotI fragment of clone 1 encompassing the entire open reading frame and 478-2763 bp of the sequence. PGK-MITF-2A contains the entire open reading frame in the 1.8-kb Sall/NotI fragment of clone 3. PGK-MITF-2B is identical to PGK-MITF-2B except that the EcoRV fragment of clone 2, 277 bp exchanged from clone 3 into clone 1. This removed the R5RS5 encoding sequence found from 2161 to 2172 bp in clone 1. Myc-MITF-2B contains six tandem copies of the 11-α-amino acid human c-myc epitope (Evan et al., 1985) fused in frame to the N terminus of MITF-2B, adding a total of 89 amino acids upstream of MITF-2B. Myc-MITF-2B contains the same c-myc tag fused to a XhoI site downstream of MITF-2B. Thus MITF-2BΔ lacks the first 83 amino acids found in MITF-2B. PGK-MITF-2B contains a 930-bp BamHI/XhoI fragment of Id cDNA (Benezra et al., 1990). PGK-E12 contains a 1.4-kb EcoRI fragment of a partial E12 cDNA (Murre et al., 1989a). The partial E12 cDNA was previously subcloned downstream of and in frame with an initiator methionine (Murre et al., 1989a) creating an expression construct missing the first 208 amino acids of the full-length E12. PGK-MyoD and PGK-CAT contain the pgk-1 promoter sequences driving MyoD and CAT cDNAs, respectively, and CA-LacZ contains 440 bp of the human cardiac α-actin promoter driving the Escherichia coli lacZ gene (Pari et al., 1991).

**Cell Culture and Transfections—**P19 embryonal carcinoma cells were cultured as described previously (Rudnicki and McBurney, 1987). Cells were transfected by the calcium phosphate method (Chen and Okayama, 1987). For transient transfections, 106 cells in 5 ml of medium in a 60-mm dish were exposed to a DNA precipitate for 6–8 h containing 5 µg of CA-LacZ, 1 µg of PGK-CAT, with or without 1.5 µg of PGK-MyoD and specified amounts of PGK-MITF-2B, PGK-MITF-2A, PGK-ID, or PGK-E12. Each transfection contained a total of 15 µg of DNA, completed by including sufficient quantities of pGEM vector DNA (Pharmacia). Cells were harvested 24 h after transfection.

β-Galactosidase and CAT assays were performed as described previously (Norton and Coffin, 1985; Slegier, 1986). Each β-galactosidase assay was normalized for transfection efficiency with the CAT activity from that transfected culture. The PG1[MyoD] cell line stably expresses MyoD and has been described previously (Skerjanc et al., 1994). Differentiation was induced by plating 5 × 104 P19 or PG1[MyoD] cells into 60-mm dishes containing either 1 µM retinoic acid or 0.8% Me2SO. Cells were cultured as aggregates for 5 days and then plated in tissue culture dishes and harvested for RNA on day 6. Me2SO treatment under these conditions induces cardiac muscle in P19 cells and skeletal muscle in P19[MyoD] cells. Retinoic acid treatment induces neuroectoderm in P19 cells and a mixture of neuroectoderm and skeletal muscle in P19[MyoD] cells (Skerjanc et al., 1994).

**RNase Protection**—In order to produce the desired antisense RNA for RNase protection, a 1206-bp Sall/StI fragment of MITF-2B (clone 1) was subcloned into Bluescript vector (KS orientation, Stratagene Cloning Systems, La Jolla, CA), and called MITF-2B/(1,1206). MITF-2B/(1,1206) was linearized with BspI and from pTrI-β-actin-mouse plasmid DNA using T7 RNA polymerase, as described in the MAXIscript in vitro transcription kit protocol (Ambion Inc, Austin, TX). Incorporation of radioactivity was checked by trichloroacetic acid precipitation, and the RNA probes were purified from a 5% acrylamide-8 M urea gel as described in RPA II, ribonuclease protection assay kit (Ambion). The MITF-2B/(1,1206) probe was optimized for RNase digestion. The probe was 3′ end labeled with γ-32P ATP using the exchange reaction with bacteriophage T4 polynucleotide kinase, as described previously (Sambrook et al., 1989). The labeled 1-kb ladder was subjected to
electrophoresis alongside the RNase protection samples. A graph of log molecular weight versus distance from the origin was used to determine the sizes of the RNase-resistant fragments. The calculated molecular weights agreed with the predicted molecular weights within an error of 10%.

RESULTS

Cloning Mouse ITF-2—We set out to determine the spectrum of bHLH proteins present in differentiating cultures of P19 cells by using degenerate oligonucleotide primers from the bHLH region to amplify bHLH cDNAs from a library of cDNA made from P19 cultures (Skerjanc and McBurney, 1994). No cDNAs encoding novel bHLH proteins were found; only cDNAs encoding E type bHLH proteins were identified. One class of amplified cDNA was derived from the mouse homologue of ITF-2. This ITF-2 probe was used to screen a cDNA library in bacteriophage λ made from Me2SO-treated P19 cells. Three cDNA clones were isolated, subcloned, and sequenced on both strands. They derive from two alternatively spliced forms of mouse ITF-2 mRNA, and the relationship of the three clones to these alternatively spliced forms is summarized in Fig. 1A.

Clone 1 contains both upstream and downstream stop codons along with an open reading frame predicting a 670-amino acid protein. It has a truncated 3'-untranslated region, probably because the oligo(dT) cDNA primer initiated reverse transcription at an internal A-rich sequence. Clone 2 contains a partial coding region and an extended 3'-untranslated region. The nucleotide and amino acid sequence for clones 1 and 2 were designated MITF-2A and MITF-2B and are shown in Fig. 1B.

Clone 3 also contains both upstream and downstream stop codons and an open reading frame identical to that of clone 1 except in two regions. The first 159 bp of clone 3 is different from that of clone 1 and predicts a protein with a different N terminus that we designated MITF-2A (Fig. 1C). In addition, clone 1 contained 12 nucleotides inserted 50 bp upstream of the bHLH domain that were absent from clones 2 and 3. These 12 nucleotides encode the four amino acids, RSRS, indicated in Fig. 1, A and B. Clones 1 and 3 contain an LH motif, which is the presumptive transcriptional activation domain (Quong et al., 1993).

Comparison of MITF-2 with Other E Type bHLH cDNAs—cDNAs derived from the human and dog homologues of MITF-2 have been cloned previously. A comparison of nucleic acid sequence between these ITF-2 clones and MITF-2 is outlined in Fig. 2. The nucleotide similarity index for various regions of the cDNAs has been calculated by the method of Wilbur and Lipman (1983). MITF-2B appears to be the same splice variant as SEF2-1B (Corneliussen et al., 1991), while MITF-2A appears to be the same splice variant as SEF2-1A (Corneliussen et al., 1991). However, MITF-2A contains 142 bp of novel 5'-sequence, including the first 17 amino acids, an initiator methionine, and an upstream stop codon. HUMITF-2 (Henthorn et al., 1990a) is a partial cDNA and appears to be identical to MITF-2B and SEF2-1B but missing the first 49 amino acids. SEF2-1D and TFE (Javaux et al., 1991) appear to be different splice variants.

The RSRS sequence is found in three of the seven cDNAs from the ITF-2 gene and appears to derive from a mini-exon that may or may not be included.

The 3'-untranslated region of MITF-2A/B is about 1 kb longer than the sequences cloned previously. A remarkable sequence identity (93–95%) was found in the 3'-untranslated regions of ITF-2 from the different species. The 5' sequences are the least conserved with only 39–45% homology for SEF2-1A, B, and D with MITF-2B.

The extent of nucleic acid homology between the related but distinct gene products, HEB (Hu et al., 1992) and E12 (Nourse et al., 1990), with MITF-2B is also shown in Fig. 2. These cDNAs show less homology in the coding region (61–80%), with the greatest similarity in the bHLH domain. The 5' and 3'-untranslated regions have very low homology (39–48%) with MITF-2B. Neither cDNA contains the RSRS domain.

Activity of MITF-2—MITF-2A and -2B were examined for their abilities to transactivate the cardiac α-actin promoter when transfected into cells with or without MyoD. MyoD alone transactivated the cardiac α-actin promoter 10-fold over background, while neither MITF-2A nor MITF-2B activated the cardiac α-actin promoter significantly (Fig. 3A). Co-transfecting MITF-2A with MyoD had no effect on MyoD-induced cardiac α-actin promoter activity; however, co-transfection of MITF-2B with MyoD resulted in less promoter activity than that induced by MyoD alone. A similar inhibition of MyoD activity was found by co-transfection of Id with MyoD (Fig. 3A). Thus, despite their similarity, it seems that MITF-2A and -2B do not have the same activity as transcription factors.

MITF-2A and -2B encode proteins identical but for two regions. The N termini are different, and MITF-2B contains the 4 amino acids, RSRS, just upstream of the bHLH domain. In order to determine which of these two regions is responsible for the MITF-2B inhibition of MyoD activity, the 12 bp encoding the RSRS sequence were removed from MITF-2B, in a construct called MITF-2BΔ. MITF-2BΔ, like MITF-2B, inhibited MyoD activity (Fig. 3A). Since MITF-2BΔ is identical to MITF-2A in all regions except the first 182 amino acids, the inhibitory activity of MITF-2B must require the amino-terminus domain.

To further define the inhibitory domain, the first 83 amino acids of MITF-2BΔ were deleted and replaced with six copies of the 11-amino acid c-myc epitope (Evan et al., 1985) creating Myc-MITF-2BΔN. As a control, this c-myc tag was fused to the N terminus of intact MITF-2B creating Myc-MITF-2B. The MyoD activation of the cardiac α-actin promoter was reduced to 17% by MITF-2B but to only 78% by Myc-MITF-2BΔN (Fig. 3B). This suggests that the inhibitory domain resides in the first 83 amino acids of MITF-2B. The Myc-MITF-2B reduced promoter expression by an intermediate amount (47%), suggesting that the c-myc tag may interfere with the region near the N terminus that mediates transcriptional inhibition.

Id is thought to inhibit MyoD activity by forming inactive heterodimers with E type bHLH proteins, sequestering them away from MyoD (Benezra et al., 1990). In agreement with this model, an excess of E12 reversed the Id inhibition (Fig. 4). An excess of MITF-2A also reversed Id inhibition (Fig. 4), suggesting that E12 and MITF-2A can heterodimerize with Id and/or MyoD. However, neither E12 nor MITF-2A was able to reverse the inhibition created by MITF-2B (Fig. 4).

Distribution of MITF-2 Splice Products—Since MITF-2B appears to inhibit E box-mediated transactivation (Fig. 3) while MITF-2A is an activator (Fig. 4), we set out to determine if the expression of these forms was regulated in a tissue-specific manner. RNase protection was performed by hybridizing various RNA samples with an antisense riboprobe comprising nucleotides 478-1206 of MITF-2B (Fig. 1A). The MITF-2A transcript is predicted to protect a 134-nucleotide fragment, while the MITF-2B transcript is predicted to give a 728-nucleotide protected fragment. When compared with [γ-32P]ATP-labeled 1-kb ladder standards, the calculated molecular sizes of the protected bands obtained agreed with the predicted sizes.

We examined RNA from several cell types and tissues. We found that MITF-2B transcripts, indicated as the labeled band 1, were present in all cell types examined, including P19 stem cells (lane 1 and 2), P19-derived cardiac muscle (lane 3), P19[MyoD]-derived skeletal muscle (lane 4), P19- (lane 5), and P19[MyoD]- (lane 6) derived neuroectoderm, mouse brain (lane
Protection of a riboprobe prepared from β-actin cDNA indicated that all of the samples contained equal amounts of mRNA (Fig. 5B).

The level of MITF-2A mRNA was variable in the samples analyzed. MITF-2A transcripts were present in all samples containing neurons (Fig. 5A, lanes 5–7, band 5). Barely detectable levels were found in liver (Fig. 5A, lane 8, band 5). Thus, MITF-2A seems to be expressed at high levels only in cells of the neuroectoderm lineage.

Band 3 appears to derive from MITF-2 transcript spliced to yield the D isoform represented by SEF2–1D (Fig. 2). This band was detected in all cell types and was elevated about 7-fold in brain tissue (lane 7).

Fig. 1. Panel A, schematic outline of the relationship between the three cloned cDNAs and MITF-2A and MITF-2B. Untranslated regions are indicated as gray boxes, the LH domain as a striped box, and the bHLH domain as a black box. The RSR5 domain is shown as a triangle in clone 1. The unique 5'9 sequence of MITF-2A is shown as a wavy line in clone 3 and as a boldface box in MITF-2A. Restriction sites used in subcloning are indicated.

Panel B, the nucleotide and amino acid sequences of MITF-2B. The LH, RSRS, and bHLH domains are indicated by shaded areas between nucleotides 1532 and 1741, 2160 and 2172, and 2222 and 2401. The position at which MITF-2A becomes identical to MITF-2B is shaded at nucleotide 1072. Amino acid residues are presented in capital letters using the single-letter code, and nucleotides are in small letters.

Panel C, the unique 5' nucleotide and amino acid sequence of MITF-2A. The sequence of MITF-2A that is identical to MITF-2B is shaded, starting at nucleotide 60.

The transcript was undetectable in P19 stem cells, P19-derived cardiac muscle and P19-derived skeletal muscle (Fig. 5A, lanes 1p4, band 5). Thus, MITF-2A seems to be expressed at high levels only in cells of the neuroectoderm lineage.

Band 3 appears to derive from MITF-2 transcript spliced to yield the D isoform represented by SEF2–1D (Fig. 2). This band was detected in all cell types and was elevated about 7-fold in brain tissue (lane 7).
Two additional bands, 2 and 4, were detected in all cells, representing MITF-2 transcripts with 5' ends derived from as yet unidentified exons.

**DISCUSSION**

We cloned 3 cDNAs containing sequences encoding the bHLH region of the mouse ITF-2 protein. These cDNAs were derived from two alternatively spliced transcripts called MITF-2A and MITF-2B. Neither MITF-2A nor MITF-2B encoded a protein that by itself activated expression of the cardiac α-actin promoter. In fact, the MITF-2B protein inhibited MyoD-induced expression from the cardiac α-actin promoter, while the MITF-2A protein did not. The inhibitory activity of MITF-2B requires the first 83 amino acids at its amino terminus. The MITF-2A protein is a transcription activator because it activated cardiac α-actin promoter expression when co-expressed in cells along with MyoD and Id. Thus, the MITF-2A and MITF-2B proteins arise from the same gene by differential splicing or different promoter usage and encode transcription factors that activate and repress expression, respectively.
Alternative Splicing of ITF-2

In the legend to Fig. 3 with and without 1.5 Radiolabeled antisense riboprobes for MITF-2B (ity by Id but not by MITF-2B. P19 cellswere transfected as described in the text. The sizes of the bands, determined by comparison with a radiolabeled 1-kb ladder, are indicated on the right, and the corresponding bands were visualized by autoradiography. The cDNAs are indicated on the left. All samples were digested with RNase, except lane 10, which is a control for riboprobe integrity. Samples were separated by electrophoresis on an acrylamide/urea gel, and the corresponding cDNAs are indicated on the left.

Both MITF-2B and Id inhibited MyoD activity, but they appear to do so by different mechanisms. While the inhibitoryactivity of Id was effectively lost in the presence of excess E12 or MITF-2A, these latter two proteins were unable to reverse the inhibition of MITF-2B. We interpret our results as suggesting that Id inhibits primarily by sequestering the “active” E type proteins from MyoD, while MITF-2B seems to inhibit by forming stable heterodimers directly with MyoD.

Although we found that MITF-2B inhibited MyoD activation of the cardiac α-actin promoter, human ITF-2 protein cooperated with MyoD to activate promoters containing an E box in COS cells (Lassar et al., 1991). The HITF-2 used in these experiments was encoded by a cDNA that was not full-length and contained a synthetic initiation codon resulting in a protein, which lacked 49 amino acids from the N terminus when compared with MITF-2B. Since the inhibitory activity of MITF-2B resides in the N-terminal 83 amino acids, the critical inhibitory domain may be absent from the HITF-2 used in these experiments. Alternatively, P19 stem cells may contain a different complement of bHLH proteins to those in COS cells, resulting in inhibition by ITF-2 in one system and activation in the other. Evidence that the two cell types contain different bHLH proteins derives from the finding that MyoD transfected alone is not active in COS cells but is active in P19 cells (Lassar et al., 1991; Pari et al., 1991; Skerjanc and McBurney, 1994).

Other transcription factors are alternatively spliced to create one form that activates and another form that inhibits transcription. However, the splicing usually involves the removal of an activation domain, resulting in a shorter form, which is an inhibitor, and a longer form, which is an activator. For example, FosB undergoes alternative splicing to remove a C-terminal transcriptional activation domain, creating ΔFosB, which is a transcriptional repressor (for review, see Foulkes and Sassone-Corsi (1992)). TFE3 is a bHLH leucine zipper transcription factor that binds to the intronic enhancer of the immunoglobulin heavy chain gene. Alternative splicing at the N terminus removes the first 105 nucleotides and creates an inhibitor of transcription (Roman et al., 1991). Finally, the retinoic acid receptors γ1 and γ2 undergo alternative splicing in which different N-terminal amino acids produce transcriptional repressors or activators (Husmann et al., 1991).

Apart from differences at their 5′-ends, cDNAs from mouse and human ITF-2 may or may not contain a 12-bp sequence in the coding region 50 bp upstream of the bHLH domain. These 12 bp encode the 4 amino acids RSRS, but the role, if any, of this tetrapeptide in MITF-2A activity remains unclear.

The transcripts encoding MITF-2A and MITF-2B appear to be present in most cell types and tissues investigated, making it difficult to deduce the roles of these transcription factors in regulating expression of E box containing genes. Given that many transcription factors are regulated post-transcriptionally, such as by phosphorylation or protein turnover, it seems possible that the inhibitory and activation effects of MITF-2 isoforms might be subject to additional means of modulation.

Acknowledgments—We thank Ken Garson and Ted Hutchinson for critically reading the manuscript, H. Weintraub and R. Benezra for providing Id cDNA, T. Braun for E12 cDNA, and T. Marshall for mouse tissue RNA. We also thank Gila Messer for preparation and analysis of Myc-MITF-2B. The expert technical assistance of Karen Jardine is gratefully acknowledged.

REFERENCES

Aistra, C. N., Baer, P. H., and McBurney, M. W. (1987) Genes Dev. 1, 65–74

Auffray, C., and Rougon, F. (1988) Eur. J. Biochem. 170, 303–314

Benezra, R., Davis, R. L., Lockshon, D., Turner, D. L., and Weintraub, H. (1990) Cell 63, 49–59

Braithwaite, D., Buschhausen-Denker, G., Bober, E., Trumpf, E., and Arnold, H. H. (1989) EMBO J. 8, 701–709

Braun, T., Bovenkamp-Denker, G., Bober, E., and Arnold, H. H. (1990) EMBO J. 9, 821–831

Chen, C., and Okayama, H. (1987) Mol. Cell. Biol. 7, 2745–2752

Chen, Q., Cheng, J.-T., Tsai, L., Schneider, N., Buchanan, G., Carroll, A., Crist, W., Ozanne, B., Siciliano, M. J., and Baer, R. (1990) EMBO J. 9, 415–424

Cornelissen, B., Thornel, A., Hallberg, B., and Grundstrom, T. (1991) J. Virol. 65, 6084–6093

Fig. 4. E12 and MITF-2A reverse the inhibition of MyoD activity by Id but not by MITF-2B. P19 cells were transfected as described in the legend to Fig. 3 with and without 1.5 μg of PGK-MyoD, 1.5 μg of PGK-Id or PGK-MITF-2B, and 6 μg of PGK-E12 or PGK-MITF-2A, as indicated. Error bars represent standard error calculated from between four and 10 different experiments.

Fig. 5. RNase protection demonstrates that MITF-2B is widely expressed. Radiolabeled antisense riboprobes for MITF-2B (panel A) or β-actin (panel B) were hybridized to 5 μg of RNA from P19 stem cells (lane 1), P19(MyoD) stem cells (lane 2), P19-derived cardiac muscle (lane 3), P19(MyoD)-derived skeletal muscle (lane 4), P19-derived neuroectoderm (lane 5), P19(MyoD)-derived neuroectoderm and skeletal muscle (lane 6), mouse brain (lane 7), mouse liver (lane 8), and torula yeast (lane 9). All samples were digested with RNase, except lane 10, which is a control for riboprobe integrity. Samples were separated by electrophoresis on an acrylamide/urea gel and visualized by autoradiography. The sizes of the bands, determined by comparison with a radiolabeled 1-kb ladder, are indicated on the right, and the corresponding cDNAs are indicated on the left.

lipid by Id but not by MITF-2B. P19 cellswere transfected as described in the legend to Fig. 3 with and without 1.5 μg of PGK-MyoD, 1.5 μg of PGK-Id or PGK-MITF-2B, and 6 μg of PGK-E12 or PGK-MITF-2A, as indicated. Error bars represent standard error calculated from between four and 10 different experiments.

Fig. 5. RNase protection demonstrates that MITF-2B is widely expressed. Radiolabeled antisense riboprobes for MITF-2B (panel A) or β-actin (panel B) were hybridized to 5 μg of RNA from P19 stem cells (lane 1), P19(MyoD) stem cells (lane 2), P19-derived cardiac muscle (lane 3), P19(MyoD)-derived skeletal muscle (lane 4), P19-derived neuroectoderm (lane 5), P19(MyoD)-derived neuroectoderm and skeletal muscle (lane 6), mouse brain (lane 7), mouse liver (lane 8), and torula yeast (lane 9). All samples were digested with RNase, except lane 10, which is a control for riboprobe integrity. Samples were separated by electrophoresis on an acrylamide/urea gel and visualized by autoradiography. The sizes of the bands, determined by comparison with a radiolabeled 1-kb ladder, are indicated on the right, and the corresponding cDNAs are indicated on the left.

Both MITF-2B and Id inhibited MyoD activity, but they appear to do so by different mechanisms. While the inhibitoryactivity of Id was effectively lost in the presence of excess E12 or MITF-2A, these latter two proteins were unable to reverse
A Splice Variant of the ITF-2 Transcript Encodes a Transcription Factor That Inhibits MyoD Activity
Ilona S. Skerjanc, James Truong, Pascale Filion and Michael W. McBurney

J. Biol. Chem. 1996, 271:3555-3561.
doi: 10.1074/jbc.271.7.3555

Access the most updated version of this article at http://www.jbc.org/content/271/7/3555

Alerts:
- When this article is cited
- When a correction for this article is posted

Click here to choose from all of JBC’s e-mail alerts

This article cites 44 references, 22 of which can be accessed free at http://www.jbc.org/content/271/7/3555.full.html#ref-list-1